After a median treatment duration of 15 weeks with a period of 17.2-month median follow-up, the objective response rate was 23% in all patients, 39% in patients with UTUC, and 28% in patients with no less than 5% of PD-L1 expression on tumor-infiltrating immune cells, with complete responses observed in 11 patients (9%). The gene discussed is CD274; the disease is neoplasm.